@article{oai:air.repo.nii.ac.jp:00002780,
 author = {ARATA, Suguru and OHSHIMA, Shigetoshi and GOTO, Takashi and MIURA, Kouichi and KOMATSU, Masafumi and NAKANE, Kunio and YAGISAWA, Hitoshi and TAWARAYA, Hironobu and NAKAJIMA, Kou and FUNAOKA, Masato and HOSHINO, Takao and KURAMITSU, Tomoyuki and FUJISHIMA, Yuukou and WATANABE, Daisuke and AJIMINE, Takuma and OHNISHI, Hirohide},
 issue = {1},
 journal = {秋田医学},
 month = {Jun},
 note = {AIM : To compare the efficacy and safety of triple therapy with simeprevir (SMV) against triple
therapy with telaprevir (TPV) while treating chronic hepatitis C (CHC).
METHOD : A total of 230 CHC patients were enrolled in the present study. One hundred
forty-three patients were treated with TPV, and 87 patients were treated with SMV. Univariate
analyses were performed to evaluate the pretreatment factors contributing to a sustained virological
response at 24 weeks after the end of treatment (SVR24) and adverse events in the TPV and
SMV groups.
RESULT : The SVR24 rates in the TPV and SMV groups were 81.1% and 76.8%, respectively.
The difference was not statistically significant. In the TPV group, the rates of anemia, nausea
and renal dysfunction were significantly higher than those in the SMV group.
CONCLUSION : In the present study, the SVR24 rates achieved by the two therapies did not
differ to a statistically significant extent. However, the rates of some adverse events in the TPV
group were significantly higher than those in the SMV group. SMV was associated with low risk
and a high SVR24 rate in patients with HCV.},
 pages = {29--37},
 title = {A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR},
 volume = {43},
 year = {2016}
}